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Introduction: If sympathetic hyperactivity seems to be associated to
several components of the metabolic syndrome, its involvement in the deve-
lopment of metabolic syndrome has not been clearly defined.
Aim: It was to determine if a chronic increase of the sympathetic nervous
activity is a sufficient condition for the development of metabolic disorders. For
that purpose, we used a transgenic mouse model, in which the gene coding for
the reuptake norepinephrine transporter (NET) has been deleted; these animals
display increased plasma catecholamine rates, associated to slight increases in
blood pressure and heart rate. We focused on the consequences of this sympa-
thetic hyperactivity on glucose and lipid metabolism in this mouse model.
Methods: Heterozygous NET knockout mice (+/-) or wild-type mice (+/+)
were fed either with a normal chow or a 30% w/v fructose in drinking water
during a period of 15 weeks to induce metabolic disorders. Metabolic para-
meters (plasma triglycerides and total cholesterol, intraperitoneal glucose
tolerance test, IPGTT) were measured after a 4h fasting period before treat-
ment and then repeated every 5 weeks.
Results: No significant difference on triglycerides or cholesterol rates
could be detected after the 15 weeks period. Heterozygous mice displayed
clear glucose intolerance already before starting the fructose diet (area under
the curve (%)=25434 vs 20822, p=0.013 for +/- and +/+ mice respectively).
These animals were also much more sensitive to high fructose, since a 50%
increase in the area under the curve of the IPGTT was obtained at the end of
the high fructose diet, compared to the 11% increase in +/+ mice.
Conclusion: Our data suggest that constitutive chronic sympathetic hyper-
activity can induce the early development of carbohydrate metabolism disor-
ders. Moreover, it seems to represent a major factor of susceptibility to diet-
induced metabolic dysfunction.
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Introduction: Determination of adipose tissue proportion, as well as its
spatial distribution, is a major part of metabolic syndrome assessment. Various
methods, commonly used in mouse models, are either indirect measurement,
invasive (destructive) or imaging techniques. Indirect measurement tech-
niques, such as deuterium dilution (considered as gold standard) or bioim-
pedance are based on the measurement of body composition. They give access
to the measure of total body fat, without distinction between visceral and sub-
cutaneous fat volumes. Sacrifice and ex-vivo tissue weight allow both total fat
measurement and partition between subcutaneous and visceral fat pad. It is a
direct method that does not allow for longitudinal studies. Non-invasive
micro-imaging modalities (magnetic resonance imaging and μCT) add, over
others, the advantage of spatial localization of fat, in vivo.
Aim: Of our study was to compare results of measurements of total body
fat done by μCT and bioimpedance in mice.
Methods: μCT was done using a dedicated in vivo imaging instrument
(eXplore Vision 120, GE, USA) on 30 anesthetized mice. Each acquisition
lasted approximately 12 min. Just after μCT, measurement of body composi-
tion was performed by bioimpedance (ImpediVET, ImpediMed, USA).
Results: The average value of total body fat by μCT is 5% higher than that
obtained by bioimpedance. The standard deviation calculated from μCT mea-
surements is lower than that obtained with bioimpedance (4.8% vs 6.8%
respectively). The linear correlation of μCT and bioimpedance measure of
total adipose tissue is moderate (r² = 0.55). 
Conclusion: It is the first time, to our knowledge, that a comparison of
total fat volume measurement between μCT and bioimpedance is performed in
mice. Surprisingly, the correlation appears not to be so trivial between the
2 methods. Before a deeper exploration, comparison of results obtained with
these 2 methods should be made with caution.
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Background: Psoriasis is a chronic inflammatory disease associated with
multiple comorbidities that are components of the metabolic syndrome (MS).
Several studies have objectified a high prevalence of MS in psoriasis patients.
Objective: To determine the prevalence of MS and its components in pso-
riasis patients compared with controls, also the factors determinants the occur-
rence of MS in our patients.
Patients and Methods: This was a prospective study including 100 psori-
asis patients versus 100 controls seen in consultation or in hospitals.
Conducted for a period of 12 months.
Results: The prevalence of MS was higher in patients with psoriasis
compared with controls (OR=2.89, p=0,0002). With a significant increase in
obesity (OR=3.25, p=0.001), hypertriglyceridemia (OR=3.9, p=0.013) and
glucose intolerance (OR = 2.13, p = 0.046). Risk factors determining the
appearance of SM in psoriatic were age, family history of psoriasis, seniority
of psoriasis, but we did not find a correlation with sex, severity of psoriasis
and the clinical form.
Conclusion: The management of psoriasis will integrate research risk fac-
tors for a possible metabolic syndrome and its treatment through a multidisci-
plinary approach.
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Metabolic Syndrome (MetS) is a cluster of metabolic risk factors,
including visceral obesity and insulin resistance (IR), associated with a higher
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risk for cardiovascular events. Adipose tissue plays a central role in the obe-
sity-related metabolic abnormalities and it’s known that Mineralocorticoid
Receptor (MR) activation affects adipocyte differentiation and function. In
particular, MR blockade has shown significant promise in limiting adipocyte
dysfunction and MetS in preclinical models. Moreover it has been shown that
adipose tissue secretome shows a paracrine effect on vascular system and car-
diac function. In our study we showed that MR expression is increased in vis-
ceral adipose tissue (VAT) in a preclinical mouse model of MetS and in obese
patients. Thus, we generated a double transgenic mouse model with a condi-
tional and inducible overespression of MR in adipose tissue, demonstrating
that, even in the absence of high fat diet HFD, increased expression of MR in
adipose tissue contributes to MetS development with multiple metabolic
abnormalities, including visceral obesity and body weight gain, glucose
intolerance and insulin resistance as well as dyslipidemia. Moreover we iden-
tified prostaglandin D2 synthase (PTGDS) as a novel MR target gene in adi-
pocytes and AT56, a specific inhibitor of PTGDS enzymatic activity, blunted
adipogenic aldosterone effects. Finally, translational studies showed that
expression of MR and PTGDS are strongly correlated in adipose tissues from
obese patients. In consideration of our results other analyses are necessary to
investigate the effect of the MR overexpressing model-specific adipokine pro-
file on cardiac function. Of particular interest will be the study of the cross-
talk between the epicardial adipose tissue (EAT) and the adjacent myocardium
by using supernatants obtained from MR overexpressing mice EAT incubation
to test the paracrine effect of adipokines on cardiac myocytes function.
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Background/Objectives: Lymphocytes play a critical role in visceral adi-
pose tissue inflammation. The CD28 costimulatory molecule is required for
lymphocyte activation and for the development of a functional regulatory T
cells (Treg) compartment; however its role during obesity is unknown.
Methods: During diet-induced obesity, we investigated the effects of
selective interference with CD28 signaling using knock-out mice (Cd28KO)
and a CTLA4-Ig fusion protein inhibiting CD28-B7 interactions.
Results: Cd28 deficiency decreased pathogenic T-cells and Treg content
within adipose tissue without changing macrophages number. Cd28KO epi-
didymal but not subcutaneous fat was characterized by enlarged adipocytes,
reduced levels of inflammatory cytokines and increased Glut4, adiponectin
and lipogenic enzymes mRNA levels. This was associated with reduced
inflammation, fat accumulation and enhanced glucose metabolism in liver.
Weight gain and fasting glucose tolerance were not affected. CTLA4-Ig injec-
tions reduced the number T-cells in epididymal adipose tissue but not inflam-
matory cytokines levels and failed to improve liver fat accumulation.
Conclusions: Deletion of CD28 creates a new pro/anti-inflammatory
balance in epididymal adipose tissue and liver and exerts a protective effect
against hepatic steatosis.
0321
Imidazoline-like drug improves insulin sensitivity through a direct sti-
mulation of adiponectin secretion in primary adipocytes
Maud Weiss, Florian Traversi, Pascal Bousquet, Hugues Greney, Nathalie
Niederhoffer
Labo de Neurobiologie et Pharmacologie Cardiovasculaire (EA 7296),
Strasbourg, France
Introduction: Altered adiponectin signaling has been proposed as a key
factor in the development of metabolic syndrome. We previously showed that
one imidazoline I1 receptor (I1R) ligand, LNP509, can improve insulin sensi-
tivity and glucose tolerance partly through increased adiponectin plasma level.
The objective of this study was to explore direct actions of I1R ligands on adi-
pocytes.
Methods: Experiments were carried out in primary adipocytes isolated
from the epididymal white adipose tissue of aged male Wistar rats. Expression
of I1R on adipocytes was verified with binding assays. I1R ligand effect was
evaluated by treating adipocytes with increasing concentrations of LNP509
±I1R antagonist efaroxan (10-4 M). To identify the intracellular signaling path-
ways involved in the action of LNPs, wortmannin (PI3K-inhibitor), IBMX
(phosphodiesterase blocker) and AS1842856 (FOXO1 inhibitor) were added
45 min prior LNP509 exposure. After 3h, adiponectin content was measured
in the culture medium by ELISA assay.
Results: Competition binding assays confirmed the expression of I1R in adipo-
cyte membrane. Treatment by LNP509 dose-dependently induced adiponectin
secretion: from 18±5 ng/ml at 10-9 M to 66±15 ng/ml at 10-4 M; p≤0.05 vs medium
alone (25 ng/ml). The adiponectin secretion induced by the highest LNP509
concentration was similar to the one elicited by 10 μM insulin (61 ng/ml); the
secretion was totally prevented by a pretreatment with efaroxan (10-4 M). The
LNP509-induced adipokine secretion was unchanged by wortmannin, but was
reduced after phosphodiesterase and FOXO1 blockade (–80% and –44% respec-
tively, compared to LNP509 alone).
Conclusion: LNP509, through I1R, promotes adiponectin secretion by
inhibiting cAMP and SIRT1/FOXO1 pathways. These effects could lead to
PPARγ  activation in order to promote adiponectin synthesis. Future studies
should confirm the proposed signaling pathways.
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